News & Perspective

Dec 09, 2015

Dec 09, 2015

Flu Scan for Dec 09, 2015

Egg allergies and LAIV
More avian flu in France
Avian flu in Taiwan, Germany, Russia

Oct 27, 2014

Oct 27, 2014

CSL-Novartis deal includes US cell-based flu vaccine plant

The $275 million deal will make the company the second leading player in the $4 billion global flu vaccine market.

Feb 14, 2013

Feb 14, 2013

Euro studies show flu vaccine working best against type B

(CIDRAP News) – New European studies reported today in Eurosurveillance suggest that this year's influenza vaccine is providing good protection against influenza B viruses but only moderate protection against type A—findings more or less consistent with earlier results in the United States.

Feb 11, 2011

Feb 11, 2011

Study showing high effectiveness for H1N1 vaccine stirs debate

(CIDRAP News) – A recent case-control study estimates that the adjuvanted pandemic H1N1 influenza vaccine used in Canada was effective 93% of the time, a substantially higher figure than seen in several other studies and one that has raised some eyebrows among other flu vaccine researchers.

Oct 06, 2010

Oct 06, 2010

Trial answers some, not all, questions on cell-based flu vaccines

(CIDRAP News) – A new report says that a cell culture derived influenza vaccine and a conventional egg-based vaccine both proved effective in a large international clinical trial, offering support for those who contend that cell-based vaccines should become an important part of flu vaccine supplies in coming years.

Aug 06, 2009

Aug 06, 2009

WHO says H1N1 vaccine process won't sacrifice safety

(CIDRAP News) – The World Health Organization (WHO) said today that the fast-tracking of vaccines for pandemic H1N1 influenza won't compromise safety, while acknowledging that clinical data will be limited when the first doses are administered.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Apr 05, 2007

Apr 05, 2007

Firm seeks US license for seasonal flu vaccine

(CIDRAP News) – CSL Biotherapies, the US branch of an Australian vaccine producer, announced this week it has applied for Food and Drug Administration (FDA) approval to market a seasonal influenza vaccine in the United States.

Pages

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»